靶向糖尿病肾病中的细胞衰老:再生、细胞治疗及其他衰老治疗策略的潜力
本文综述了细胞衰老在糖尿病肾病(DKD)发病中的作用,并总结了近五年针对衰老负担的衰老治疗药物(senolytics与senomorphics)及再生治疗(如间充质干细胞、细胞外囊泡、水凝胶与支架)等新兴策略,提出将衰老治疗特性与再生药物结合的新思路,以阻止DKD进展。
要点
- 细胞衰老是DKD病理的驱动因素,通过促炎导致组织损伤。
- 衰老治疗药物分为senolytics和senomorphics,直接减少衰老负担。
- 再生治疗包括间充质干细胞、细胞外囊泡及水凝胶支架等处于早期临床试验。
核心结论
- 靶向细胞衰老的衰老治疗药物和再生治疗是阻止DKD进展的潜在新策略。
研究设计与样本
- 综述总结了近五年关于DKD细胞衰老及新型治疗平台的研究。
主要发现
- 细胞衰老是DKD发病的公认驱动因素,可传播慢性炎症导致组织损伤。
- 衰老治疗药物包括senolytics和senomorphics,直接减少衰老负担。
- 再生治疗涵盖间充质干细胞/基质细胞及其细胞外囊泡、水凝胶和支架等生物材料,部分已在DKD早期临床试验中。
- 其他先进技术如CAR-T、CRISPR基因编辑和AAV基因递送提供减少衰老和炎症的新机会。
临床怎么用
- 关注衰老治疗药物与再生治疗联合策略,以最大化阻止DKD进展的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic kidney disease (DKD) is the primary cause of chronic kidney disease globally. Although modern treatments can slow the progression of DKD, a substantial number of individuals still advance to kidney failure each year, attributed to complex, multifactorial pathophysiological processes that confer treatment resistance. Cellular senescence, an irreversible state of cell cycle arrest, has emerged as a recognized driver of DKD pathogenesis, which propagates chronic inflammation, leading to tissue damage. Over the past 5 years, investigations into novel therapeutic platforms that diminish senescence in DKD models and patients have increased exponentially. Senotherapeutics are agents that directly reduce senescence burden and can be classified as senolytics and senomorphics. Regenerative therapeutics encompass disciplines like cell-based therapies and tissue engineering, which aim to restore damaged tissues. Commonly studied cellular therapies in DKD include mesenchymal stem/stromal cells and their derived extracellular vesicles. Tissue engineering leverages biomaterials, like hydrogels and scaffolds, some of which are also in early-phase clinical trials for DKD. Other advanced technologies, including chimeric antigen receptor T cell, clustered regularly interspaced short palindromic repeats gene editing, and adeno-associated virus-mediated gene delivery, offer unique opportunities to expand the DKD armamentarium to reduce cellular senescence abundance and chronic inflammation. In this review, we summarize recent studies characterizing cellular senescence in DKD, highlight senescence-associated molecules and pathways comprising therapeutic targets, describe promising senotherapeutics and regenerative agents under investigation, and propose new strategies that magnify senotherapeutic properties in regenerative agents for maximized impact to halt DKD. These scientific advancements and others are expected to contribute to the development of new therapeutic agents that address cellular senescence and prevent DKD pathogenesis.
引用
- Patel HA, Wang J, Zinn CJ, et al. Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches. Kidney Int. 2026. PMID: 41581730. doi:10.1016/j.kint.2025.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。